GeneSight

MYRIAD TUESDAY DEADLINE: ROSEN, A GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of November 26th Deadline in Securities Class Action | PR Newswire | 11/26/2019

… ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of …

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SEE, MYGN, ZEN and YJ | Globe Newswire | 11/26/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

Follow GeneSight:    

CLASS ACTION UPDATE for CVET, MYGN, ZEN and PLT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders | Globe Newswire | 11/25/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

MYGN FINAL DEADLINE: ROSEN LAW FIRM Reminds Myriad Genetics, Inc. Investors of Tuesday Deadline in Securities Class Action – MYGN | Globe Newswire | 11/25/2019

… ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of …

SHAREHOLDER ALERT: MYGN TEUM ACB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines | The Wapakoneta Daily News | 11/25/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl-and thereby, Foresight-caused …

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MYGN, CC and ET | The Wapakoneta Daily News | 11/25/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl-and thereby, Foresight-caused …

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MYGN, DOMO and PLT | The Wapakoneta Daily News | 11/24/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | PR Newswire | 11/23/2019

… be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. On September 1, 2016 , Myriad announced the completion of its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with two new products—ForeSight and Prelude—in the expanded carrier screening …

4-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | Globe Newswire | 11/23/2019

SAN FRANCISCO, Nov. 22, Hagens Berman urges Myriad Genetics, Inc. (NASDAQ: MYGN) investors who have suffered losses in excess of $50,000 to submit their losses now or contact the firm immediately to learn if they qualify to recover compensable damages. The November 26, 2019 lead plaintiff deadline in a securities fraud class action pending against the company is approaching. Class Period: Sept. 2, 2016 – Aug. 13, 2019 Lead Plaintiff Deadline …

3-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | 11/23/2019

510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint, Defendants misled investors about Myriad Genetics’ GeneSight®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight® product, while concealing that GeneSight® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that …

7-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | 11/22/2019

510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint, Defendants misled investors about Myriad Genetics’ GeneSight®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight® product, while concealing that GeneSight® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that …

5-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | 11/22/2019

510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint, Defendants misled investors about Myriad Genetics’ GeneSight®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight® product, while concealing that GeneSight® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that …

CLASS ACTION DEADLINE: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines to File Lead Plaintiff Motions Related to the Following Companies: MYGN, OSTK, MTCH | 11/22/2019

… September 2, 2019 and August 13, 2019 Deadline: November 26, 2019 According to the complaint, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the FDA had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii …

DEADLINE ALERT - Myriad Genetics, Inc. (MYGN) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: November 26, 2019 | Globe Newswire | 11/22/2019

… recover damages against Defendants for alleged violations of the federal securities laws. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of …

6-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | 11/21/2019

510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint, Defendants misled investors about Myriad Genetics’ GeneSight®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight® product, while concealing that GeneSight® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that …

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MYGN, CC and RUHN | 11/21/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl-and thereby, Foresight-caused …

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADTN, MTCH, MYGN and UA | Globe Newswire | 11/21/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

MYGN ALERT: Zhang Investor Law Reminds Investors of NOVEMBER 26 Deadline in Securities Class Action Lawsuit Against Myriad Genetics, Inc. – MYGN | Globe Newswire | 11/21/2019

… the class action. 如果您想加入这个集体诉讼案,请在这里提交您的信息。 http://zhanginvestorlaw.com/join-action-form/?slug=myriad-genetics-inc&id=2034 . According to the case, defendants made false and/or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of …

CLASS ACTION UPDATE for SNDL, MYGN, DOMO and ET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders | Globe Newswire | 11/21/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN | Globe Newswire | 11/20/2019

… psychotropic drug selection for depressed patients; and Foresight, a prenatal test in the expanded carrier screening market for future parents to assess their risk of passing on a recessive genetic condition to their offspring. GeneSight is offered as both a psychotropic 1 test (“GeneSight Psychotropic”) and MTHFR (an enzyme required to convert folic acid and dietary folate into its active form, which is called l-methylfolate) test. On September 1 …

Food and Drug Administration

MYRIAD TUESDAY DEADLINE: ROSEN, A GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of November 26th Deadline in Securities Class Action | PR Newswire | 11/26/2019

GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (3) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (4) Myriad’s acquisition of Counsyl – and thereby, Foresight – caused the Company to incur …

Molecular Diagnostics

Q2 2020 EPS Estimates for Myriad Genetics, Inc. (NASDAQ:MYGN) Cut by Svb Leerink | 11/23/2019

… ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. Get a free …

Myriad Genetics Shareholders: November 26, 2019 Filing Deadline in Class Action – Contact Lieff Cabraser | 11/22/2019

… toll-free at 1-800-541-7358. Myriad, incorporated and headquartered in Salt Lake City, Utah, is a molecular diagnostic company that develops and markets predictive, personalized, and prognostic medicine tests. Myriad offers, among other products, GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients, and Foresight, a test for future parents to assess their risk of passing on a recessive genetic condition to their offspring. The action alleges …

Diagnostic Tests

Q2 2020 EPS Estimates for Myriad Genetics, Inc. (NASDAQ:MYGN) Cut by Svb Leerink | 11/23/2019

… diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for …

Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients Nasdaq:MYGN | Globe Newswire | 11/21/2019

… company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

Precision Medicine

Treading with Caution | 11/22/2019

… determine whether a drug will be an effective treatment for their patients. “It seemed that [the FDA’s] actions had taken precision medicine in the wrong direction,” Genomind CEO Shawn Patrick O’Brien told Clinical OMICs. In … developers supporting AMP’s “best practices” statement is Myriad Genetics. Its GeneSight Psychotropic Test is a laboratory-developed pharmacogenomic test designed to measure and analyze clinically important genomic variants in treating psychiatric disorders. “As a laboratory …

Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients Nasdaq:MYGN | Globe Newswire | 11/21/2019

… 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

Medicare

Treading with Caution | 11/22/2019

… their medication plan are warranted. Supporting best practices Among test developers supporting AMP’s “best practices” statement is Myriad Genetics. Its GeneSight Psychotropic Test is a laboratory-developed pharmacogenomic test designed to measure and analyze clinically … the FDA.” In addition to UHC, GeneSight is covered by Medicare, CareFirst, and Kroger Health. “We have ongoing conversations with other health plans,” Rogers said. “Payers and providers have consistently noted that they are most …

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of VRAY, MYGN and ZEN | 11/11/2019

… or failed to disclose that: (a) demand for ViewRay systems had declined due in part to changes being made to Medicare reimbursement approaches first announced in November 2019 that could make purchases of new ViewRay … statements and/or failed to disclose that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration …

Pharmacogenomic Testing

Dr. Mark H. Pollack named Chief Medical Officer for Myriad NeuroscienceHighly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice | BioSpace | 10/21/2019

Dr. Mark H. Pollack named Chief Medical Officer for Myriad NeuroscienceHighly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice Published: Oct 21, 2019 SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Mark H. Pollack, M.D., chief medical officer of Myriad Neuroscience effective Jan. 15 …

Kroger Health and Myriad Genetics Launch Pilot Program to Improve the Treatment of Depression | PR Newswire | 7/10/2019

CINCINNATI , July 10, Kroger Health, the healthcare arm of The Kroger Co. providing health, wellness, and nutrition solutions to more than 14 million people nationwide, announced its partnership with Myriad Genetics to pilot Myriad Genetics’ GeneSight® pharmacogenomic test with Kroger Prescription Plan members. Nearly 500 Kroger pharmacies across five states will participate in the GeneSight pilot. GeneSight is the market-leading genetic test to help clinicians personalize treatment plans for …

Henry Schein

CLASS ACTION UPDATE for CVET, MYGN, ZEN and PLT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders | The Wapakoneta Daily News | 11/25/2019

… capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein’s Animal Health Business and VFC, including the timing and nature of those costs … period and/or failed to disclose that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration …

CLASS ACTION UPDATE for CVET, MYGN, ZEN and PLT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders | Benzinga | 11/25/2019

… capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein’s Animal Health Business and VFC, including the timing and nature of those costs … period and/or failed to disclose that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration …

Assurex Health

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | PR Newswire | 11/23/2019

… Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with two new products—ForeSight and Prelude—in the expanded carrier screening and non-invasive prenatal testing markets, respectively. The company estimated that these markets would grow to approximately three million tests performed in the U.S. and $1.5 billion …

EndoPredict

Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients Nasdaq:MYGN | Globe Newswire | 11/21/2019

… EndoPredict, Vectra, GeneSight, riskScore, Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Lynparza is a registered trademark of AstraZeneca. Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Japan’s Ministry of Health …

Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients | Markets Insider | Business Insider | 11/21/2019

… EndoPredict, Vectra, GeneSight, riskScore, Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Lynparza is a registered trademark of AstraZeneca. Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Japan’s Ministry of Health …

UnitedHealth

Myriad Genetics Limps Into Fiscal 2020 | Yahoo News | 8/15/2019

… Myriad also disclosed an update in its communications with the U.S. Food and Drug Administration regarding requested changes to the GeneSight Psychotropic test, which helps patients determine the most effective treatment for depression and is … which matches individuals to depression treatments, would be covered by UnitedHealthcare . The news sent shares soaring nearly 60% as investors clamored over the idea that more major insurers would follow suit and help unlock the …

Myriad Genetics faces risk after FDA asks for GeneSight test changes - Business Insider | 8/14/2019

The pioneering genetic-testing company Myriad Genetics sells a test called GeneSight that claims to analyze a patient’s DNA and point them to the best depression drug for them. Scientists and doctors have raised concerns … Tycho Peterson and his team said. This news comes after UnitedHealth Group, the nation’s largest health insurer, said it would start covering GeneSight and other such tests for certain patients, starting in October. Myriad Genetics …

UnitedHealthcare

Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results | BioSpace | 11/5/2019

GeneSight ® Announced coverage decision from UnitedHealthcare, the largest commercial payer in the United States, covering GeneSight for patients that have a diagnosis of major depressive disorder or anxiety and have failed at least one prior medication. Signed master service agreement with a large pharmacy benefit manager in the United States to offer GeneSight to its commercial payer and self-funded employer customers. A Fortune 50 company has already opted into …

Genetic Tests For Psychiatric Drugs Now Covered By Some Insurers : Shots - Health News : NPR | 10/17/2019

… Meehan, an industry analyst for Barclays. Myriad reported that it sold $113 million worth of the tests. In addition to UnitedHealthcare’s coverage, Myriad Genetics’ test is covered by Medicare, a regional Blue Cross Blue Shield … says of all the tests claiming to improve depression treatment, GeneSight’s has the most proof. That isn’t saying much, though. “I wouldn’t say there’s no evidence that it works,” he says. “It’s just the evidence …

Bragar Eagel

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | PR Newswire | 11/23/2019

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm News provided by Nov 23, 2019, 12:00 ET … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

Robert S. Willoughby

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN | Globe Newswire | 11/20/2019

Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Myriad is a molecular diagnostic company that develops and markets predictive, personalized, and prognostic medicine tests worldwide. Myriad offers, among other products, GeneSight, a DNA …

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN | Benzinga | 11/20/2019

Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Myriad is a molecular diagnostic company that develops and markets predictive, personalized, and prognostic medicine tests worldwide. Myriad offers, among other products, GeneSight, a DNA …

Phillip Kim

MYGN LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. – MYGN | Business Wire | 9/28/2019

… the federal securities laws. To join the Myriad class action, go to http://www.rosenlegal.com/cases-register-1685.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class … or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration …

Colleen Lindholz

Here’s what Kroger stands to gain from its new partnership with Myriad Genetics (KR) | Business Insider | 7/16/2019

… chain Kroger announced it’s teaming up with Salt Lake City-based genetic testing company Myriad Genetics to bring the company’s GeneSight test to select members of Kroger’s employee health plan, per MedCity News. Business Insider … pension costs.” And in a press release , Kroger Health President Colleen Lindholz called depression — which affects over 17 million people in the US — the No. 1 cause of disability and lost productivity in the country …

Kroger Health and Myriad Genetics Launch Pilot Program to Improve the Treatment of Depression | PR Newswire | 7/10/2019

GeneSight® pharmacogenomic test with Kroger Prescription Plan members. Nearly 500 Kroger pharmacies across five states will participate in the GeneSight pilot. GeneSight is the market-leading genetic test to help clinicians personalize treatment plans for their patients with depression. “Depression is a leading cause of disability and lost productivity in the United States , and only 40 percent of people reach remission after their first antidepressant medication,” said Colleen Lindholz , President …